Low miR-221 expression in aggressive PCa characterized by VEGFR2 overexpression not only marks patients with a significantly higher risk of progression [12], but those most likely to benefit from anti-angiogenic therapy. The gene discussed is KDR; the disease is posterior cortical atrophy.